Truist raised the firm’s price target on Inspire Medical to $280 from $265 and keeps a Buy rating on the shares. The analyst cites the company having reported its first positive operating profit, also noting that the firm was encouraged by the management’s commitment to sustaining operating profit and positive EPS in the second half of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSP:
- Lost Money in MBLY, BNTX, DADA, INSP or ON? Class Action Suits Filed, Seeking Recovery
- Inspire Medical Systems Engages Investors with Upcoming Meetings
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Reaffirms 2024 Outlook
- Inspire Medical resumed with an Overweight at KeyBanc
- Inspire Medical Announces Leadership Changes and New Chair
